Coloplast Valuation
Is 0QBO N undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0QBO N when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0QBO N (MX$2082.59) is trading above our estimate of fair value (MX$1147.88)
Significantly Below Fair Value: 0QBO N is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0QBO N?
Key metric: As 0QBO N is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0QBO N's PE Ratio? | |
|---|---|
| PE Ratio | 40x |
| Earnings | DKK 4.80b |
| Market Cap | DKK 192.27b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.9x |
| Enterprise Value/EBITDA | 27.4x |
| PEG Ratio | 3.6x |
Price to Earnings Ratio vs Peers
How does 0QBO N's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 41.5x | ||
COO Cooper Companies | 55.1x | 23.0% | US$19.8b |
ALC Alcon | 36.7x | 9.4% | CHF 37.8b |
7741 HOYA | 35.5x | 11.6% | JP¥7.0t |
ALGN Align Technology | 38.9x | 17.5% | US$16.7b |
0QBO N Coloplast | 40x | 11.0% | Mex$192.3b |
Price-To-Earnings vs Peers: 0QBO N is good value based on its Price-To-Earnings Ratio (40x) compared to the peer average (69.2x).
Price to Earnings Ratio vs Industry
How does 0QBO N's PE Ratio compare vs other companies in the Global Medical Equipment Industry?
| 10 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 10 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0QBO N is expensive based on its Price-To-Earnings Ratio (40x) compared to the Global Medical Equipment industry average (29.9x).
Price to Earnings Ratio vs Fair Ratio
What is 0QBO N's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 40x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 0QBO N's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Médica Sur. de
Mex$3.1b
Operates as a healthcare hospital in Mexico.
MEDICA B
Mex$28.84
7D
1.2%
1Y
-31.0%
ZimVie
US$186.2m
Develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide.
ZIMV *
US$230.00
7D
0%
1Y
n/a
M3
JP¥880.0b
Provides medical-related services primarily to physicians and other healthcare professionals through Internet.
2413 N
JP¥183.50
7D
0%
1Y
n/a